CD4 and ductal breast carcinoma in situ: In patients with ductal carcinoma in situ (DCIS) treated with intralesional DCs, a tumor-specific CD4+ Th1 immune response was seen in the sentinel lymph node that correlated with a higher pCR rate [49].